

Kopran Lifesciences Limited
Balance Sheet as at March 31, 2016

(Amount in Rs.)

Particulars	Note No.	As at March 31, 2016	As at March 31, 2015
EQUITY AND LIABILITIES			
Shareholders' Funds			
Share Capital	2	5,00,000	5,00,000
Reserve and Surplus	3	(99,563)	(93,339)
Non- Current Liabilites			
Long-term borrowings	4	7,00,000	7,02,040
Current Liabilites			
Other Current Liabilities	5	27,312	22,312
Total		11,27,749	11,31,013
ASSETS			
Non Current Assets			
Non-current investment	6	10,00,000	10,00,000
Current Assets			
Cash and Cash Equivalents	7	1,27,749	1,31,013
Total		11,27,749	11,31,013
Notes forming part of financial statements	1-15		

As per our report of even date attached

For STDJ & Co.
Chartered Accountants




Shiv kumar Toshniwal
Partner
Membership No. 116563
Mumbai
May 28, 2016



For and on behalf of the Board of Directors



Surendra Somani
Director
DIN: 600860



Susheel G Somani
Director
DIN: 601727


Kopran Lifesciences Limited

Statement of Profit and Loss for the year ended March 31, 2016


(Amount in Rs.)

Particulars	Note No.	Year ended March 31, 2016	Year ended March 31, 2015
Income			
Revenue from operation		-	-
Total Revenue		-	-
Expenses			
Other expenses	8	6,224	13,116
Total Expenses		6,224	13,116
(Loss) Before Tax		(6,224)	(13,116)
Less : Tax Expenses		-	-
(Loss) After Tax for the year from continuing operations		(6,224)	(13,116)
Earnings Per Equity Share (Equity Shares Face value Rs.10 each) Basic and diluted		(0.12)	(0.26)
Notes forming part of financial statements	1-15		

As per our report of even date attached

For STDJ & Co.
Chartered AccountantsShiv Kumar Toshniwal
Partner
Membership No. 116563
Mumbai
May 28, 2016

For and on behalf of the Board of Director:

Surendra Somani
Director
DIN: 600860Susheel G Soma
Director
DIN: 601727

Kopran Lifesciences Limited

Cash Flow Statement for the year ended on March 31, 2016

Particulars		For the year ended March 31 2016 Rs.	For the year ended March 31 2015 Rs.
A. Cash Flow from Operating Activities			
Net Profit Before Tax and Extraordinary Items		(6,224)	(13,116)
Operating Profit before Working Capital Changes		(6,224)	(13,116)
Adjustment for :			
Increase in Current Liabilities		5,000	11,076
Net Cash flow from operating activities	A	(1,224)	(2,040)
B. Cash Flow from Investing Activities			
Advances (Given) / repaid by holding company		-	(10,00,000)
Net Cash flow provided by / (used in) Investing Activities	B	-	(10,00,000)
C. Cash Flow from Financing Activities			
Loan taken during the year		1,224	7,02,040
Loan Repayment during the year		3,264	-
Net Cash flow from Financing Activities	C	(2,040)	7,02,040
Net (decrease) / increase in Cash and Cash equivalents	(A+B+C)	(3,264)	(3,00,000)
Cash and Cash Equivalents at the beginning of the year		1,31,013	4,31,013
Cash and Cash Equivalents at the end of the year		1,27,749	1,31,013

The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Accounting Standard 3 on Cash Flow Statement.

As per our Report of even date attached

For STDJ & Co.

Chartered Accountants

Shiv

Shiv kumar Toshniwal

Partner

Membership No. 116563

Mumbai

May 28, 2016



For and on behalf of the Board of Directors

Surendra Somani
Surendra Somani
 Director

DIN: 600860

Susheel G Somani

Susheel G Somani

Director

DIN: 601727

Kopran Lifesciences Limited
Notes to Accounts forming part of the Financial Statements

Note 1: Significant Accounting Policies

a) Corporate Information

Kopran Lifesciences Limited (The Company) is a public limited company domiciled in India. It is a wholly owned subsidiary of Kopran Limited.

b) Basis of Preparation

Financial statements have been prepared in accordance with Generally Accepted Accounting Principles in India (Indian GAAP) under the historical cost convention on an accrual basis in compliance with all material aspects of the Accounting Standards (AS) specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.

c) Use of Estimates

Preparation of financial statements in conformity with IGAAP requires the management to make judgments, estimates and assumptions that affect the reported amount of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in differences between the actual results and estimates which are recognized in future periods.

d) Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the year attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

e) Provisions, Contingent Liabilities and Contingent Assets

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized, but are disclosed in the notes. Contingent Assets are neither recognized nor disclosed in the financial statements.

f) Taxation

Income tax expense comprises of current tax (i.e. amount of tax for the period determined in accordance with the Income Tax Act, 1961) and deferred tax charge or credit (reflecting the tax effect of timing differences between accounting income and taxable income for the period). Provision for current tax is made on the basis of estimated taxable income for the current accounting year in accordance with the provisions of Income Tax Act, 1961.

The deferred tax charge or credit and the corresponding deferred tax liabilities and assets are recognised using the tax rates that have been enacted or substantively enacted at the balance sheet date. Deferred tax assets are recognised only to the extent there is a reasonable certainty that the assets can be realised in future however, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets. Deferred tax assets are reviewed as at each balance sheet date and written down or written up to reflect the amount that is reasonable/virtually certain (as the case may be) to be realised.



Minimum Alternative tax (MAT) credit is recognised as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to be recognized as an asset in accordance with the recommendations contained in guidance Note issued by the Institute of Chartered Accountants of India, the said asset is created by way of a credit to the profit and loss account and shown as MAT Credit Entitlement. The Company reviews the same at each balance sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that Company will pay normal Income Tax during the specified period.

g) Investments

Investments are classified into long-term investments and current investments. Investments that are intended to be held for one year or more are classified as long-term investments and investments that are intended to be held for less than one year are classified as current investments.


Long-term investments are carried at cost less any diminution in value, other than temporary, determined separately for each individual investment.

Current investments are valued at lower of cost and market/fair value.

Profit or loss on sale of investments is determined on the basis of first in first out carrying amount of investments sold.

h) Impairment

The Company assesses at each balance sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset. If such recoverable amount of the asset or the recoverable amount of the cash-generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognised in the Statement of profit & loss. If at the balance sheet date there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount subject to a maximum of depreciated historical cost.



Kopran Lifesciences Limited

Notes forming part of Financial Statements for the year ended March 31, 2016

(Amount in Rs.)

Note 2:

Share Capital	As at March 31,2016	As at March 31,2015
Authorised		
1,00,000 Equity Shares of Rs. 10 each.	10,00,000	10,00,000
	10,00,000	10,00,000
Issued ,Subscribed and fully paid up		
50,000 Equity Shares of Rs. 10 each.	5,00,000	5,00,000
	5,00,000	5,00,000

(a)

Reconciliation of the shares outstanding at the beginning and at the end of the reporting period.	As at March 31,2016	
	Equity Shares	
	Number	(' in Rs.)
Outstanding at the beginning of the year	50,000	5,00,000
Add: Shares Issued during the year	-	-
At the end of the year	50,000	5,00,000

(b)

Terms/ rights attached to equity shares.

The company has only one class of equity shares having a par value of Rs. 10 per share. Each holder of equity share to one vote per share. The company declares and pays dividends in Indian rupees.

In the event of liquidation of company, the holders of equity shares will be entitled to receive remaining assets of t preferential amounts. The distributions will be in proportion to the number of equity shares held by shareholder.

(c)

Shares held by holding company

Particulars	As at March 31,2016	
	Equity Shares	
	Number	(' in Rs.)
Equity Shares of Rs.10 each fully paid up		
M/s Kopran Limited	50,000	5,00,000
Total	50,000	5,00,000

(d)

Details of Share holders holding more that 5% shares in the company

Particulars	As at March 31,2016	
	Equity Shares	
	Number	%
Equity Shares of Rs.10 each fully paid up		
M/s Kopran Limited	50,000	100%
Total	50,000	100%



Note 3:	Reserves and Surplus	As at March 31,2016	As at March 31,2015
	Deficit in Statement of Profit and Loss		
	As per last Balance sheet	(93,339)	(80,223)
	Deficit for the year	(6,224)	(13,116)
	Total	(99,563)	(93,339)


Note 4:	Long Terms Borrowings	As at March 31,2016	As at March 31,2015
	Unsecured Loans		
	Loan From Related Party-		
	Shri Surendra Somani	7,00,000	7,00,000
	Kopran LTD	-	2,040
	Total	7,00,000	7,02,040

Note 5:	Other Current Liabilities	As at March 31,2016	As at March 31,2015
	Other Payables	27,312	22,312
	Total	27,312	22,312

Note 6:	Non-current assets	As at March 31,2016	As at March 31,2015
	Unquoted		
	Non- Trade		
	Investment in Equity Shares		
	Others		
	1,00,000 Equity Shares of Kopran Research Laboratories Ltd of Rs. 10/- each	10,00,000	10,00,000
	Total	10,00,000	10,00,000

Note 7:	Cash and Cash Equivalents	As at March 31,2016	As at March 31,2015
	Balances with bank		
	in current Accounts	1,27,749	1,31,013
	Total	1,27,749	1,31,013

Note 8:	Other Expenses	As at March 31,2016	As at March 31,2015
	Auditor's Remuneration :		
	Statutory Audit	5,000	5,000
	Legal & Professional Charges	-	6,076
	Miscellaneous expenses	1,224	2,040
	Total	6,224	13,116



Notes to Accounts forming part of the Financial Statements

Note 9:

Estimated amount of contracts remaining to be executed on capital account and not provided for Rs. Nil (2015: Rs. NIL)

Note 10:

Contingent Liabilities not provided Rs. Nil (2015: Rs. Nil)

Note 11:

Deferred Tax

In accordance with the Accounting Standard - 22 on 'Accounting for Taxes on Income' notified by the Companies Accounting Standard Rules 2006, deferred tax assets arising on account of timing difference comprising of unabsorbed business losses have not been recognized due to lack of virtual certainty of its realisation.

Note 12:

Related Party disclosures

As required under Accounting Standard 18 "Related Party Disclosure" disclosures of transactions with the related parties are as below:


List of Related Parties

Holding Company	-	Kopran Limited
Key Management Personnel	-	Surendra Somani

During the year following transactions were carried out with the related parties in the ordinary course of business:

(Amount in Rupees)

Nature of Transactions	Holding Company	Key Management Personnel
Investment in Equity Shares	- (1,000,000)	- (-)
Loan taken	- (2,040)	- (700,000)
Loan repaid	2,040 (-)	- (-)
Balance outstanding as at March 31, 2016	- (2,040)	700,000 (700,000)



Note 13:
Computation of Earnings Per Share

Particulars	March 31, 2016	March 31, 2015
Loss after tax	(6,224)	(13,116)
Weighted average number of equity shares	50,000	50,000
Earnings per share of Rs.10/- each - Basic and Diluted (Rs.)	(0.12)	(0.26)

Note 14:

The Company has not received any intimation from suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence the disclosure, if any, relating to amounts unpaid as at the year-end together with interest paid/payable as required under the said Act have not been given.

Note 15:

Previous year figures:

Previous year figures have been recast / restated wherever considered necessary.

As per our report of even date

For **STDJ & Co.**
Chartered Accountants



Shiv Kumar Toshniwal
Partner
Membership No. 116563
Mumbai
May 28, 2016



For and on behalf of the Board of Directors of
Kopran Lifesciences Limited



Surendra Somani
Director
DIN: 600860



Susheel G Somani
Director
DIN: 601727